Secondary endpoints
SE
SECONDARY
The key secondary endpoint (CFB in HAMD-17 total score over the blinded treatment period) demonstrated a statistically significant improvement in patients who received zuranolone+ADT compared with those who received placebo+ADT over the 14 days of treatment (LS mean [SE] CFB, −11.7 [0.40] vs −10.1 [0.39]; At D15, the LS mean (SE) CFB in HAMD-17 total score was −13.7 (0.50) in the zuranolone+ADT group and −12.9 (0.49) in the placebo+ADT group (LS mean difference [SE], −0.8 [0.70]; 